Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07428447 · ClinicalTrials.gov registry record
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
A clinical trial of Essential Tremor and Essential Tremor, Movement Disorders, sponsored by CND Life Sciences.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT07428447: Recruiting study of Essential Tremor and Essential Tremor, Movement Disorders, sponsored by CND Life Sciences.
NCT07428447 is a study of Essential Tremor and Essential Tremor, Movement Disorders that is actively recruiting participants, run by CND Life Sciences. The registered enrollment target is 300 participants, below the 395-participant average among 41 other Essential Tremor trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07428447, a study of Essential Tremor and Essential Tremor, Movement Disorders, is actively recruiting participants, sponsored by CND Life Sciences.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies. Primary Objectives 1. Identify which ET patients have P-SYN pathology indicative of prodromal PD 2. Predict which patients are most likely to phenoconvert to PD
Primary Outcome
Quantity of P-SYN in biopsies as a biomarker for disease progression
Conditions Studied
Study Locations (1)
Arizona
- CND Clinical Research Center - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-02-18 |
| Est. Completion | 2029-02 |
What NCT07428447 shows while recruiting
NCT07428447 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 395-participant average among 41 other Essential Tremor trials with a reported enrollment target (24% lower).
The record links to 3 conditions, with Essential Tremor appearing as the primary indexed condition, and to 0 interventions.
NCT07428447 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT07428447 about?
NCT07428447 is a clinical study titled "Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease". Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Pos...
What is the current status of trial NCT07428447?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2026-02-18. Estimated completion is 2029-02.
What conditions does trial NCT07428447 study?
This clinical trial studies the following conditions: Essential Tremor, Essential Tremor, Movement Disorders, Essential Tremor-plus.
Who is sponsoring clinical trial NCT07428447?
This trial is sponsored by CND Life Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07428447 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Essential Tremor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07428447's enrollment target sits among peer trials
300 8th of 41 higher than 34 of 41 other Essential Tremor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Essential Tremor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor
RECRUITING
-
Circadian Adaptive DBS in Essential Tremor
RECRUITING · NA
-
Motor Network Physiology
RECRUITING · NA
-
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
RECRUITING
-
Investigating Subcortical Contributions to Speech Sequencing in Deep Brain Stimulator Recipients
RECRUITING · NA
-
3-D Tractography FUS Ablation for Essential Tremor
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI